γh2AX expression in cytological specimens as a biomarker of response to radiotherapy in solid malignancies

Diagnostic Cytopathology

Volumn 44, Issue 2, 2016, Pages 141-146

  Shah, Ketan ^a   Boghozian, Ramon A ^b   Kartsonaki, Christiana ^c   Shah, Ketan A ^d   Vallis, Katherine A ^b  

^a CHURCHILL HOSPITAL   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

biomarker; fine needle aspiration cytology; treatment monitoring; H2AX

Indexed keywords

GAMMA H2AX PROTEIN; TUMOR MARKER; UNCLASSIFIED DRUG; H2AFX PROTEIN, HUMAN; HISTONE;

ARTICLE; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RECURRENCE; CLINICAL ARTICLE; CONFOCAL MICROSCOPY; DNA STRAND BREAKAGE; FINE NEEDLE ASPIRATION BIOPSY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIATION DOSE FRACTIONATION; RADIATION RESPONSE; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; CARCINOMA, SQUAMOUS CELL; CASE REPORT; GENETICS; LUNG NEOPLASMS; LYMPHOMA, NON-HODGKIN; METABOLISM;

BIOMARKERS, TUMOR; CARCINOMA, SQUAMOUS CELL; HISTONES; HUMANS; LUNG NEOPLASMS; LYMPHOMA, NON-HODGKIN;

EID: 84954397953     PISSN: 87551039     EISSN: 10970339     Source Type: Journal    
DOI: 10.1002/dc.23396     Document Type: Article

References (13)

1. Fernandez-Capetillo O, Lee A, Nussenzweig M, Nussenzweig A., H2AX: the histone guardian of the genome. DNA Repair 2004; 3: 959-967.
2. Bonner WM, Redon CE, Dickey JS, et al., GammaH2AX and cancer. Nat Rev Cancer 2008; 8: 957-967.
3. Ivashkevich AN, Martin OA, Smith AJ, et al., gammaH2AX foci as a measure of DNA damage: a computational approach to automatic analysis. Mutat Res 2011; 711: 49-60.
4. Shah K, Cornelissen B, Kiltie AE, Vallis KA., Can gammaH2AX be used to personalise cancer treatment? Curr Mol Med 2013; 13: 1591-602.
5. Barber PR, Locke RJ, Pierce GP, Rothkamm K, Vojnovic B,. Gamma-H2AX foci counting: image processing and control software for high-content screening. Proc. SPIE 6441, Imaging, Manipulation, and Analysis of Biomolecules, Cells, and Tissues V, 64411M, 2007; doi: 10.1117/12.705217.
6. Ward IM, Minn K, Jorda KG, Chen J., Accumulation of checkpoint protein 53BP1 at DNA breaks involves its binding to phosphorylated histone H2AX. J Biol Chem 2003; 278: 19579-19582.
7. Cornelissen B, Kersemans V, Darbar S, et al., Imaging DNA damage in vivo using gammaH2AX-targeted immunoconjugates. Cancer Res 2011; 71: 4539-4549.
8. Davey E, Barratt A, Irwig L, et al., Effect of study design and quality on unsatisfactory rates, cytology classifications, and accuracy in liquid-based versus conventional cervical cytology: a systematic review. Lancet 2006; 367: 122-132.
9. Siddiqui MS, François M, Fenech MF, Leifert WR,. Persistent γH2AX: a promising miolecular marker of DNA damage and aging. Mutat Res Rev Mutat Res 2015; 766: 1-19.
10. Banuelos CA, Banath JP, Kim JY, Aquino-Parsons C, Olive PL., gammaH2AX expression in tumors exposed to cisplatin and fractionated irradiation. Clin Cancer Res 2009; 15: 3344-3353.
11. Wang LH, Pfister TD, Parchment RE, et al., Monitoring drug-induced gammaH2AX as a pharmacodynamic biomarker in individual circulating tumor cells. Clin Cancer Res 2010; 16: 1073-1084.
12. Werbrouck J, Ruyck De, Beels K, et al., Prediction of late normal tissue complications in RT treated gynaecological cancer patients: potential of the gamma-H2AX foci assay and association with chromosomal radiosensitivity. Oncol Rep 2010; 23: 571-578.
13. Garcia-Villa A, Balasubramanian P, Miller BL, Lustberg MB, Ramaswamy B, Chalmers JJ., Assessment of gamma-H2AX levels in circulating tumor cells from patients receiving chemotherapy. Front Oncol 2012; 2: 128.